Insurance start-up launches on-demand health coverage

https://www.cnbc.com/2018/06/27/insurance-start-up-launches-on-demand-health-coverage.html

Related image

 

  • Start-up Bind uses proprietary algorithms, powered by machine learning, to lower health-care costs.
  • Bind discovered that it could break out certain procedures and reduce health benefit costs more effectively than with a high-deductible plan.
  • It is backed by Ascension Ventures, Lemhi Ventures and UnitedHealthcare.

Technology has made on-demand services a reality for everything from food deliveries to gym classes and car-sharing. What if you could have on-demand health coverage for big-ticket procedures like knee surgery?

On-demand health insurance seems like an oxymoron, but digital health insurance firm Bind is betting that by structuring health plans so that people can add coverage and pay for it when they need it, companies and employees can save money in the long run.

“It’s not intuitive for people, but I think when we started this we thought, ‘how do people really use the health-care system?’ And we used it in an on-demand way,” explained Tony Miller, co-founder and CEO of Bind.

The two-year old start-up is not a full-fledged insurer, it administers benefits for self-insured employers using UnitedHealth Group’sprovider networks and data analytics. Using its own proprietary algorithms, powered by machine learning, Bind discovered that it could break out certain procedures and reduce health benefit costs more effectively than with a high-deductible plan. It is backed by Ascension Ventures, Lemhi Ventures and UnitedHealthcare.

Plans are designed with basic co-pays and no deductibles for core medical coverage. In addition to free preventive care required under the Affordable Care Act, Bind’s plans cut out deductibles for primary care and specialist visits, maternity coverage, hospital care, medications and even cancer treatment. Co-pays are priced on a sliding scale — from $15 for a visit to retail clinic to $100 at an urgent care facility.

The big-ticket out-of-pocket costs kick in for elective procedures, such as knee replacement or back surgery. The extra co-pay for those procedures is based on the total cost, with consumers being given the full price of the procedure up front and no surprise bills on the back end. The co-pay can be structured so the worker can pay it off through payroll deductions, like a premium.

By outlining the total costs, Bind said it helps employees generate 10 to 15 percent in savings for themselves and for their employer compared to traditional out-of-pocket deductible plans.

“A market might be $6,000 to $24,000 for knee arthroscopy,” explained Miller. “What Bind does is says (for) the $6,000 performer — you only have to pay $1,000 to have access to them. If you want to go to the $24,000 knee arthroscopy with no difference in quality, no difference in performance, you have to pay $6,000 as a consumer.”

“What happens is the consumers actually go and buy the more cost-effective provider and they save money. But more importantly, the entire pool saves money … we save $18,000 for the group,” he said.

That was the way high-deductible plans were supposed to work, with consumers making the most cost-effective choice. Miller should know. He co-founded Definity Health in the late 1990s, which helped pioneer so-called consumer directed health plans; UnitedHealth bought that firm in 2004.

Does he worry that employers could use Bind’s on-demand plans to skimp on core benefits, and shift more costs to their workers? He does.

“What I would worry about is, taking this very novel plan design and if someone wanted to create a skinny plan out of it,” which he admitted would defeat the goal of Bind plan designs.

“Let’s make sure we fund the things we all need in health insurance and make sure that’s a part of everyone’s core benefit,” he said.

Bind has so far signed up small regional employers for its plan, but hopes to launch with a large Fortune 500 company for 2019 coverage.

 

Theranos, founder Elizabeth Holmes and former president charged with ‘massive fraud’

https://www.bizjournals.com/sanfrancisco/news/2018/03/14/theranos-elizabeth-holmes-sunny-balwani-fraud.html?ana=e_sfbt_bn_breakingnews&u=FAuoHGaGEPdmk4X6khnaiw045b16af&t=1521046882&j=80495961

Image result for elizabeth holmes

Theranos Inc., founder Elizabeth Holmes and former President Ramesh “Sunny” Balwani were charged Wednesday by the Securities and Exchange Commission with conducting “an elaborate, years-long fraud” that raised $700 million around their needles-less blood diagnostics company.

Theranos and Holmes have agreed to “resolve” the charges against them, the agency said in a statement, which includes Holmes giving up a majority of voting control and a reduced equity stake in the company. That latter part is significant since critics of the company said change couldn’t come to the company until Holmes gave up control.

 

Report sheds light on Clover Health’s financial struggles, strategy missteps

https://www.fiercehealthcare.com/payer/clover-health-struggles-lab-bills-medicare-advantage-members?mkt_tok=eyJpIjoiWVRNeE1HSTFPREkwTmpsbSIsInQiOiJtcHFUTmw4bU5UWE0rbE44Q0ExcUc5cEI5SSt0UVdcL0ZYVDllbUhMN3VNXC9ab2JTTlwvKzVYOXMyTmVmRlwvZjJ2VzNZWmp5Z2VJeERzVytyWUZOdkVyRmdnVWNWSEV6SVhkSWVHSFljSkhRV05rMUt5WFwvemVvM2dsMEpUeW1rYUx2In0%3D&mrkid=959610

Clover Health, the Medicare Advantage startup with a data-driven strategy, is struggling financially and operationally—and in some cases, members have paid the price.

Such is the conclusion of a new report from CNBC, which relied on interviews with six anonymous former Clover employees and advisers. Here are some highlights of what they told the publication:

  • To obtain leverage over LabCorp and Quest Diagnostics in its bid to collect patient data, Clover delayed paying bills for its members’ lab tests. Some members were then “harassed with bills” from the labs—though Clover eventually paid the lab bills after learning the full extent of the issue.
  • Clover has missed its internal financial targets and other growth goals. For example, while an investor said the company predicted early on that it would book $500 million in revenue from premiums by the end of 2017, a PwC analysis found that its annual revenue is actually closer to $270 million. Its membership growth has also fallen well short of its early projections.
  • The insurer experienced a bug in one of its core software projects, which was supposed to create a list of members ranked from sickest to healthiest to call and remind about getting an annual checkup. The glitch reversed the list, resulting in Clover representatives calling the healthiest members first for several months.
  • Marco Rogers, a former senior engineer at Clover, stirred controversy online when he discussed the company’s approach to people of color. In a series of now-deleted tweets, Rogers said he was “passive aggressively pushed out by people who found me ‘adversarial.’”

Clover Health declined to comment about the claims made by CNBC’s sources. However, those are not the only struggles that Clover has had, according to previous reporting by FierceHealthcare. In 2016, the Centers for Medicare & Medicaid Services fined the company after receiving a “high volume of complaints” from new enrollees who were denied services by out-of-network providers after being told by Clover that they could see any provider they wished.

And last month, Clover co-founder and Chief Technology Officer Kris Gale stepped down from his post. Gale, who remains an adviser for the company, helped “build a foundation from which we can realize the true potential of this business,” Clover Health CEO Vivek Garipalli said in a previous statement.

However, Clover’s vision for using data analytics to disrupt the health insurance industry has won the San Francisco-based company a significant amount of investment capital. In a funding round in May, it raised $130 million, putting its total value at $1.2 billion. The insurer also began serving Medicare customers in Georgia, Texas and Pennsylvania in 2018, a significant expansion since it previously sold plans in only New Jersey.

 

Sema4, a Mount Sinai spinout, launches with a focus on genomics

Sema4, a Mount Sinai spinout, launches with a focus on genomics

dna, genomics

New York City, New York-based Mount Sinai Health System has launched a new spinout company: Sema4.

The for-profit startup has been created from numerous parts of Mount Sinai’s Department of Genetics and Genomic Sciences and the Icahn Institute for Genomics and Multiscale Biology.

Pronounced “semaphore,” the company will utilize genomic and clinical data to transform overall clinical diagnostics. By combining everything from predictive modeling to open access data, it aims to be able to better treat and diagnose diseases.

Sema4 will be run by Eric Schadt, the chair of the Department of Genetics and Genomic Sciences and the founding director of the Icahn Institute for Genomics and Multiscale Biology.

Schadt initially came to Mount Sinai about five years ago and has since helped grow its footprint in big data and genomics. But the current landscape presented an opportune time to create Sema4.

As genomic testing becomes more complex, Schadt explained, it came down to a few questions for Mount Sinai: “How do we scale all of this? How do we aggregate and manage really large scales of data and compute on it? The decision was that it’s better done as an independent company still in partnership with Sinai,” he told MedCity in a phone interview.

Mount Sinai and Sema4 will continue to be heavily involved with each other. Sema4 is the provider of all genetic testing services for Mount Sinai. And Mount Sinai will play a key role in technology development, data mining and data integration for Sema4.

“We’ll have a very, very intimate relationship,” Schadt said. “But now we are an independent, for-profit company that is presently wholly owned by Mount Sinai.”

Mount Sinai has made a large investment in Sema4 and is currently the company’s sole investor. Over the next 12 to 18 months, the startup will use those funds to grow its business, particularly its sales and marketing teams.

But after time, Sema4 will begin raising additional capital to boost the genetic testing and data sciences portions of its business.

“Once we’re stood up as a company and have our footing that way, we’ll be in a better position to more aggressively pursue the information side, and that’ll take an even bigger investment,” Schadt said.

He did not share any specific numbers with MedCity about how much Sema4 will be looking to raise.

Currently, reproductive health is a major focus area for the startup. But moving forward, Schadt said Sema4 wants to increase its involvement in the oncology space. Additionally, the company has set its sights on using digital health tools to better engage patients.

Prior to Sema4, Mount Sinai’s AppLab and Mount Sinai Innovation Partners launched a startup called Responsive Health for app distribution platform RxUniverse.

Soon-Shiong made ‘implicit threat’ to spur investment in NantHealth, media company says

Soon-Shiong made ‘implicit threat’ to spur investment in NantHealth, media company says

When Dr. Patrick Soon-Shiong invested in the troubled media company Tronc, he was greeted as a white knight. But a lawyer for Tronc is now accusing Soon-Shiong of making an “implicit threat” that he would abandon the company unless Tronc invested in his own medical diagnostics startup, NantHealth.

Soon-Shiong helped rescue Tronc from a hostile takeover attempt last May with an investment of more than $70 million. But he first tried to convince the publishing company to invest in the initial public offering of NantHealth, according to a letter from Tronc’s attorneys filed with the Securities and Exchange Commission.

“Tronc properly declined to invest in that company, since such an investment would have had no logical connection to its business operations in the publishing industry,” the attorneys wrote.

When the company declined, Soon-Shiong insisted that Michael Ferro, Tronc’s chairman, invest in NantHealth, either personally or through his private equity firm, Merrick Ventures, the attorneys wrote.

“The implicit threat was that, if Merrick did not invest in NantHealth, Dr. Soon-Shiong would not invest in Tronc,” the Tronc legal team wrote.

Ferro bought a $10 million stake in NantHealth “so that Tronc did not have to,” according to the attorneys. NantHealth went public last June, to considerable fanfare, but its stock price has since fallen by more than 60 percent.

NantHealth did not respond to a request for comment.

With NantHealth, Soon-Shiong has promised to revolutionize cancer diagnostics through a proprietary technology called GPS Cancer. But the company has struggled to gain traction, posting disappointing sales numbers and losing $184 million in 2016.

And Soon-Shiong’s management of the company has come under increasing scrutiny. Last month, a STAT investigation found that he used his highly promoted cancer moonshot initiative as a marketing vehicle for GPS Cancer. A second investigation described how Soon-Shiong used a $12 million charitable gift to funnel business into NantHealth.

The company’s stock price declined after each report, and NantHealth is now facing lawsuits from investors claiming Soon-Shiong misrepresented facts and violated securities law.

Walgreens just filed a $140 million lawsuit against Theranos

http://www.businessinsider.com/walgreens-files-lawsuit-against-theranos-2016-11?nr_email_referer=1&utm_source=Sailthru&utm_medium=email&utm_content=ScienceSelect&pt=385758&ct=Sailthru_BI_Newsletters&mt=8&utm_campaign=BI%20Science%202016-11-08&utm_term=Science%20Select%20-%20Engaged%2C%20Active%2C%20Passive%2C%20Disengaged

Elizabeth Holmes

Walgreens has filed a breach of contract lawsuit against Theranos, the embattled blood-testing startup.

The lawsuit was filed Tuesday in Delaware’s district court. Details on Walgreen’s complaint weren’t immediately available because the suit was sealed by the court.

The Wall Street Journal is reporting that Walgreens is looking for $140 million in damages, claiming that Theranos misled Walgreens about how far along its blood-testing technology was when the original partnership was inked.

Walgreens, once Theranos’ biggest partner, terminated its relationship with the company in June. It had operated Theranos Wellness Centers, where people could go have their blood tested in the company’s stores.

San Francisco health insurance startup nabs $160 million in Series C funding

http://www.bizjournals.com/sanfrancisco/blog/2016/05/clover-health-insurance-funding.html?utm_campaign=CHL%3A+Daily+Edition&utm_source=hs_email&utm_medium=email&utm_content=29844738&_hsenc=p2ANqtz-8JlwJzf_prZd5feAq2JkJrthZH5OpLmVznbwflsQbsVGtPDQe0Rit6rwfa5pLnq3ZRvU2e8JER8kPc0wgogkdDRxDRmw&_hsmi=29844738

Clover Health

Clover Health, a four-year-old health insurance startup that specializes in the Medicare managed care market, has nabbed $160 million in Series C venture funding in a round led by Greenoaks Capital.

Theranos Is the Collision of Hope and Greed

http://time.com/4301596/theranos-elizabeth-holmes-hope-greed/?utm_campaign=KHN%3A+Daily+Health+Policy+Report&utm_source=hs_email&utm_medium=email&utm_content=28784431&_hsenc=p2ANqtz-_XEQlcydlWAnTqMENKBjDPVXVdyiz_cCnhPZIizZRxkfbapGKT4me0eP56RD_wPsX3QRLRLPi_XdZbPbTAHFaVoIv_SQ&_hsmi=28784431

‘Why did we believe? We wanted it to be true.’

Harvard startup promises progress in treating deadly sepsis

http://upstart.bizjournals.com/news/technology/2015/10/09/harvard-startup-promises-progress-in-treating.html?ana=e_ptl_hc&u=FAuoHGaGEPdmk4X6khnaiw045b16af&t=1444506368&page=all

Sepsis, Wyss Institute

In the Wyss Institute’s approach to sepsis therapy, the pathogen-binding FcMBL protein is tethered to the interior of hollow fibers within the cartridge. This cartridge can be plugged into a dialysis-like extracorporeal circuit through which the blood from patients with sepsis could be run and cleansed.

A step up from Dr. Scholl’s: Baltimore devicemaker raises $2.9M for cryotherapy that freezes off malignant internal tissue

A step up from Dr. Scholl’s: Baltimore devicemaker raises $2.9M for cryotherapy that freezes off malignant internal tissue

CSA Medical spray cryotherapy